Reduced transition probabilities to the first 2(+) state in Ti-52,Ti-54,Ti-56 and development of shell closures at N=32,34

Autor: Dinca, DC, Janssens, RVF, Gade, A, Bazin, D, Broda, R, Brown, BA, Campbell, CM, Carpenter, MP, Chowdhury, P, Cook, JM, Deacon, AN, Fornal, B, Freeman, SJ, Glasmacher, T, Honma, M, Kondev, FG, Lecouey, JL, Liddick, SN, Mantica, PF, Mueller, WF, Olliver, H, Otsuka, Taka, Terry, JR, Tomlin, BA, Yoneda, K

The even 52 – 56 Ti isotopes have been studied with intermediate-energy Coulomb excitation and absolute B ( E 2; 0 + → 2 + 1 ) transition rates have been obtained. These data confirm the presence of a subshell closure at neutron number N = 32 in

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______1131::b9c3b5063feed3dcd2f35b3c6c4af72b
https://lirias.kuleuven.be/handle/123456789/493592

Comprehensive Molecular Profiling Identifies FOXM1 as a Key Transcription Factor for Meningioma Proliferation.

Autor: Vasudevan HN; Department of Radiation Oncology, University of California, San Francisco, San Francisco, CA, USA., Braunstein SE; Department of Radiation Oncology, University of California, San Francisco, San Francisco, CA, USA., Phillips JJ; Department of Pathology, University of California, San Francisco, San Francisco, CA, USA; Department of Neurological Surgery, University of California, San Francisco, San Francisco, CA, USA., Pekmezci M; Department of Pathology, University of California, San Francisco, San Francisco, CA, USA; Department of Ophthalmology, University of California, San Francisco, San Francisco, CA, USA., Tomlin BA; Department of Economics, California State University Channel Islands, Camarillo, CA, USA., Wu A; Department of Radiation Oncology, University of California, San Francisco, San Francisco, CA, USA., Reis GF; Department of Pathology, University of California, San Francisco, San Francisco, CA, USA., Magill ST; Department of Neurological Surgery, University of California, San Francisco, San Francisco, CA, USA., Zhang J; Department of Neurological Surgery, University of California, San Francisco, San Francisco, CA, USA., Feng FY; Department of Radiation Oncology, University of California, San Francisco, San Francisco, CA, USA., Nicholaides T; Department of Neurological Surgery, University of California, San Francisco, San Francisco, CA, USA., Chang SM; Department of Neurological Surgery, University of California, San Francisco, San Francisco, CA, USA., Sneed PK; Department of Radiation Oncology, University of California, San Francisco, San Francisco, CA, USA., McDermott MW; Department of Neurological Surgery, University of California, San Francisco, San Francisco, CA, USA., Berger MS; Department of Neurological Surgery, University of California, San Francisco, San Francisco, CA, USA., Perry A; Department of Pathology, University of California, San Francisco, San Francisco, CA, USA; Department of Neurological Surgery, University of California, San Francisco, San Francisco, CA, USA., Raleigh DR; Department of Radiation Oncology, University of California, San Francisco, San Francisco, CA, USA; Department of Neurological Surgery, University of California, San Francisco, San Francisco, CA, USA. Electronic address: david.raleigh@ucsf.edu.

Publikováno v: Cell reports [Cell Rep] 2018 Mar 27; Vol. 22 (13), pp. 3672-3683.